CLD-501

About Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage biotechnology company with a mission to revolutionize the treatment of solid tumors and metastatic cancers through its innovative stem cell-based delivery platforms. The company's core achievement is the development of the RedTail platform, a 'Trojan horse' system that protects oncolytic viruses from immune clearance, enabling systemic administration to target disseminated disease. Its strategy involves advancing a pipeline of candidates, including the lead program CLD-401, through clinical development while exploring the platform's utility in oncology and beyond. Having gone public in 2023, Calidi is positioned to leverage its novel technology in the competitive field of cancer immunotherapy.

Therapeutic Areas